AtaiBeckley (ATAI) Income from Non-Controlling Interests (2020 - 2026)
AtaiBeckley (ATAI) recorded quarterly Income from Non-Controlling Interests of -$20000.0 in Q1 2026, up 41.18% quarter-over-quarter from -$34000.0 in Q1 2025, and up 41.18% on a YoY basis from -$14166.7 in Q1 2025.
AtaiBeckley (ATAI) Income from Non-Controlling Interests (2020 - 2026) Analysis & Trends
AtaiBeckley has disclosed Income from Non-Controlling Interests across 6 years of filings, most recently posting -$24000.0 for Q3 2025.
- Income from Non-Controlling Interests for Q3 2025 came in at -$24000.0, up 4.0% year-over-year; the trailing twelve-month figure through Sep 2025 was -$108000.0 (up 93.24% YoY), and the FY2024 annual result was -$780000.0, up 78.75% from the prior year.
- Income from Non-Controlling Interests was -$20000.0 for Q1 2026 at AtaiBeckley, up from -$34000.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of -$20000.0 in Q1 2026 to a low of -$34000.0 in Q1 2025.
- The 5-year median for Income from Non-Controlling Interests is -$677000.0 (2022), against an average of -$615666.7.
- Across the five-year window, Income from Non-Controlling Interests tumbled 48500.0% in 2021 and jumped 97.14% in 2024, its largest moves.
- AtaiBeckley's Income from Non-Controlling Interests stood at -$4.4 million in 2021, then jumped by 62.74% to -$1.6 million in 2022, then soared by 48.11% to -$850000.0 in 2023, then soared by 96.12% to -$33000.0 in 2024, then gained by 27.27% to -$24000.0 in 2025.
- The last three Income from Non-Controlling Interests figures came in at -$24000.0 (Q3 2025), -$17000.0 (Q2 2025), and -$34000.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.75 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | AtaiBeckley | 1.45 Bn | 1.45 Bn | - | -20,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20,000.00 |
| Sep 30, 2025 | -24,000.00 |
| Jun 30, 2025 | -17,000.00 |
| Mar 31, 2025 | -34,000.00 |
| Mar 31, 2025 | -34,000.00 |
| Dec 31, 2024 | -33,000.00 |
| Sep 30, 2024 | -25,000.00 |
| Jun 30, 2024 | -57,000.00 |
| Mar 31, 2024 | -665,000.00 |
| Dec 31, 2023 | -850,000.00 |
| Sep 30, 2023 | -873,000.00 |
| Jun 30, 2023 | -729,000.00 |
| Mar 31, 2023 | -1.22 Mn |
| Dec 31, 2022 | -1.64 Mn |
| Sep 30, 2022 | -1.81 Mn |
| Jun 30, 2022 | -891,000.00 |
| Mar 31, 2022 | -689,000.00 |
| Dec 31, 2021 | -4.40 Mn |
| Sep 30, 2021 | -484,000.00 |
| Mar 31, 2021 | 3.36 Mn |